Discontinued — last reported Q2 '19
Medtronic Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) increased by 38.9% to $1.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 42.6%, from $3.30B to $1.90B. Over 4 years (FY 2021 to FY 2025), Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) shows a downward trend with a -9.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher values suggest prolonged exposure to unfavorable interest rate environments or potential long-term asset devaluation.
This metric tracks the unrealized losses on available-for-sale debt securities that have been in a loss position for twe...
Used by analysts to evaluate the 'stickiness' of unrealized losses in the investment book.
afs_debt_securities_unrealized_loss_12m_or_longer| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.95B | $5.48B | $2.86B | $5.00B | $5.07B | $5.13B | $4.81B | $4.76B | $4.79B | $4.74B | $3.95B | $4.30B | $3.27B | $3.14B | $3.30B | $2.99B | $2.43B | $1.36B | $1.90B |
| QoQ Change | — | +38.5% | -47.8% | +75.1% | +1.4% | +1.1% | -6.3% | -1.0% | +0.5% | -1.0% | -16.7% | +8.8% | -23.8% | -4.1% | +5.2% | -9.3% | -18.7% | -43.9% | +38.9% |
| YoY Change | — | — | — | — | +28.3% | -6.3% | +68.2% | -4.9% | -5.6% | -7.6% | -17.9% | -9.7% | -31.6% | -33.8% | -16.4% | -30.3% | -25.6% | -56.5% | -42.6% |